Breast Cancer, Version 3.2018

• DOI: 10.6004/jnccn.2019.0009
• Publication Date: 2019-02-20T20:25:53Z
• Authors: Matthew P. Goetz; William J. Gradishar; Benjamin O. Anderson; Jame Abraham; Rebecca Aft; Kimberly H. Allison; Sarah L. Blair; Harold J. Burstein; Chau Dang; Anthony D. Elias; William B. Farrar; Sharon H. Giordano; Lori J. Goldstein; Steven J. Isakoff; Janice Lyons; P. Kelly Marcom; Ingrid A. Mayer; Meena S. Moran; Joanne Mortimer; Ruth M. O'Regan; Sameer A. Patel; Lori J. Pierce; Elizabeth C. Reed; Hope S. Rugo; Amy Sitapati; Karen Lisa Smith; Mary Lou Smith; Hatem Soliman; Melinda L. Telli; John H. Ward; Jessica S. Young; Dorothy A. Shead; Rashmi Kumar
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.